- MCI’s investment supports the growth of Ariel while supporting MCI’s future entry for MCI into the US market
- This investment will advance MCI’s precision medicine and technology roadmap by accelerating both clinical and commercial projects
- Jessica Gibson, Ariel’s Co-Founder and CEO will join MCI as an advisor
- MCI is a healthcare technology company
- Ariel is an innovative precision medicine company
- MCI Onehealth Technologies Inc. (DRDR) opened trading at C$3.11 per share
The investment supports Ariel’s growth and paves the way for MCI to enter the United States market.
This investment is anticipated to advance MCI’s precision medicine and technology roadmap by accelerating both clinical and commercial projects with pharmaceutical, medical device and life sciences companies.
“The addition of Ariel’s solution into MCI’s increasingly advanced clinical tool kit will create real benefit for our patients by speeding up time to diagnosis and bringing in more accurate and targeted therapy,” said Dr. Alexander Dobranowski MD., CEO of MCI.
“As we explore a commercial pilot with Ariel, we’re thrilled to have Jessica Gibson, Ariel’s Co-Founder and CEO, bring her experience and unique expertise to MCI in an advisory capacity.”
Ariel is integrating genetic data into clinical decision-making, empowering doctors and patients to prevent, mitigate or even reverse disease progression.
Ariel’s innovations enable evidence-based, patient-specific treatment decisions by bringing together the most advanced insights. Ariel’s artificial intelligence technologies analyze complex gene-to-gene interactions as well as lifestyle and environmental factors to provide a more comprehensive view of disease trajectory and precise therapeutic options.
“Ariel combines genetic and clinical information into disease models to help identify early symptoms of disease and develop patient centered therapies,” said Jessica Gibson, Ariel’s Co-Founder and CEO.
“Both MCI and Ariel share the goal of getting such tools into the hands of primary care providers to improve health outcomes and cost. The combination of MCI’s clinical network and Ariel’s platform will empower both physicians and patients with insights into each patient’s unique health needs and support evidence-based decisions for disease prevention and treatment.”
MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs.
Ariel is an innovative precision medicine company, transforming genetic and clinical data into new insights for the diagnosis and advanced therapeutic alignment and development for complex health conditions.
MCI Onehealth Technologies Inc. (DRDR) opened trading at C$3.11 per share.
